Nexavar (sorafenib tosylate) — United Healthcare
fallopian tube cancer
Preferred products
- topotecan
Initial criteria
- Diagnosis of ovarian cancer OR fallopian tube cancer OR primary peritoneal cancer
- AND Patient has persistent or recurrent disease
- AND Disease is platinum‑resistant
- AND Used in combination with topotecan
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Nexavar therapy
Approval duration
12 months